OLMA — Olema Pharmaceuticals Cashflow Statement
0.000.00%
- $335.52m
- -$98.57m
- 34
- 37
- 45
- 32
Annual cashflow statement for Olema Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -22.1 | -71.1 | -105 | -96.7 | -129 |
Depreciation | |||||
Non-Cash Items | 3.75 | 17.4 | 19.3 | 13.1 | 15.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.5 | 2.83 | 3.02 | -0.589 | 9.16 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -19.9 | -50.7 | -82.1 | -83.7 | -104 |
Capital Expenditures | -0.056 | -1.57 | -0.363 | 0 | -0.159 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -274 | 91.8 | -4.85 | -93.4 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.056 | -275 | 91.5 | -4.85 | -93.5 |
Financing Cash Flow Items | — | — | — | 130 | 244 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 358 | 1.39 | 0.476 | 133 | 269 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 338 | -325 | 9.89 | 44.8 | 70.9 |